Aligos Therapeutics, Inc.
ALGS
Revenue
1.06M
▲367.00k▲52.88%
3 Months ChangeAssets
108.81M
▼-19.09M▼-14.93%
3 Months ChangeLiabilities
41.58M
▼-26.52M▼-38.95%
3 Months ChangeFree Cash Flow
-22.39M
▼-1.45M▼-6.90%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-09-05
Form 8-K
ID: 0001193125-24-214188
2024-08-19
Form 8-K
ID: 0001193125-24-202813
2024-08-08
Form 8-K
ID: 0001193125-24-196966
2024-08-06
Form 10-Q
ID: 0000950170-24-091828
2024-08-06
Form 8-K
ID: 0001171843-24-004482
2024-06-28
Form 8-K
ID: 0001193125-24-172218
2024-05-31
Form 8-K
ID: 0001193125-24-151729
2024-05-22
Form 8-K
ID: 0001193125-24-144929
2024-05-15
Form 8-K
ID: 0001193125-24-139476
2024-05-07
Form 10-Q
ID: 0000950170-24-054497